Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Takeda Presents TAK-875 Data

By Drug Discovery Trends Editor | June 29, 2011

Takeda Pharmaceutical announced results from data presented by Takeda Global Research & Development Center, Inc. that evaluated the safety, tolerability and hemoglobin A1c (HbA1c) lowering activity for TAK-875, an investigational compound for the treatment of type 2 diabetes.

 TAK-875 is the first GPR40 agonist to reach clinical development and completed studies have demonstrated glucose-lowering effects in patients with type 2 diabetes by stimulating glucose-dependent insulin secretion.

Agonists of GPR40, one of the G-protein-coupled receptors expressed in pancreatic islet cells, have a novel mechanism of action for type 2 diabetes. They work by selectively improving glucose-dependent insulin secretion with a low risk of inducing hypoglycemia, which is different from the mechanisms of sulfonylurea or incretin hormones.
 
The data were presented from a Phase 2 randomized, double-blind, placebo- and active (glimepiride) comparator-controlled, parallel-group, multicenter study, which was conducted to evaluate the efficacy, safety and tolerability of once-daily treatment with five different doses of TAK-875 over 12 weeks. The primary efficacy endpoint was the change from baseline in HbA1c levels at week 12.

Study results found that all doses of TAK-875 showed significantly greater HbA1c reductions at week 12 versus placebo, and the magnitude of decrease in HbA1c produced by TAK-875 ?50 mg was comparable to glimepiride at week 12. Compared to placebo, approximately twice as many subjects treated with TAK-875 ?25 mg achieved HbA1c less than seven percent at week 12, similar to glimepiride. The incidence of hypoglycemia was significantly lower for all doses of TAK-875 (2.3%) compared to glimepiride (16.1 percent) and similar to placebo (3.3% ). Treatment-emergent adverse events ranged from 43.5% to 61.3% and were highest with glimepiride. There was minimal discontinuation due to adverse events (1.6-3.3 percent) among all active treatment groups.

Release Date: June 28, 2011
Source: Takeda Pharmaceutical 


Filed Under: Drug Discovery

 

Related Articles Read More >

Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE